Clinuvel Pharmaceuticals to Move Headquarters to US, Plan Workforce Reduction of Up to 20%

MT Newswires Live
Jul 23

Clinuvel Pharmaceuticals (ASX:CUV) said it will relocate its corporate headquarters to the US from Jan. 1, 2027, as the company restructures operations to support US market expansion and enhance access to capital, according to a Thursday Australian bourse filing.

The company will reduce its global workforce by around 10% to 20% and redirect resources toward its US-focused pharmaceutical pipeline, with a particular emphasis on late-stage vitiligo programs, the filing said.

The company said the move is driven by stronger US investor demand, deeper specialty pharmaceutical capital markets, and the potential for higher valuation multiples than Australian Securities Exchange-listed peers, the filing added.

Clinuvel Pharmaceuticals' shares added 2% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10